Innovating Works

WMU

ExoDiagAI: Empowering Personalized Therapeutics: Advancing 3D-Nano DLD Arrays and Raman Micro-Biochips for Prec... UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un HORIZON EUROPE HORIZON-MSCA-2023-PF-01 The ExoDiagAI project is at the forefront of addressing a critical challenge in modern healthcare—early diagnosis and effective management o...
2024-05-14 - 2026-07-14 | Financiado
ETUDE: Encompassing Training in fUnctional Disorders across Europe UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020 H2020-MSCA-ITN-2020 Functional Disorders (FD) are clusters of chronic somatic symptoms that currently cannot be associated to reproducibly observable pathophysi...
2020-09-04 - 2024-12-31 | Financiado
HEARTBIT_4.0: HeartBIT 4.0 Application of innovative Medical Data Science technologies for heart diseases. UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU tramitó un H2020 H2020-WIDESPREAD-2018-2020 Support of medical care requires new skills related to effective control of applied medication and methods of treatment, elimination of mutu...
2019-07-11 - 2022-12-31 | Financiado
ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020 H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado
REGIONS4PERMED: INTERREGIONAL COORDINATION FOR A FAST AND DEEP UPTAKE OF PERSONALISED HEALTH UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020 H2020-SC1-BHC-2018-2020 Personalised medicine (PM) represents a paradigm shift away from a ‘one size fits all’ approach to the treatment and care of patients with a...
2018-10-19 - 2023-04-30 | Financiado
RECOMB: Stem cell based gene therapy for recombination deficient SCID RECOMB UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020 H2020-SC1-2016-2017 Gene therapy for rare inherited immune disorders has become a clinical reality. Especially for SCID, two major types of SCID (ADA-SCID, X-SC...
2017-11-21 - 2024-12-31 | Financiado
BETA3_LVH: A multi center randomized placebo controlled trial of mirabegron a new beta3 adrenergic receptor a... UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020 H2020-PHC-2014-2015 Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fra...
2015-04-15 - 2022-08-31 | Financiado
SECURE: Secondary prEvention of CardiovascUlaR disease in the Elderly trial UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un H2020 H2020-PHC-2014-2015 While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overal...
2015-04-08 - 2021-12-31 | Financiado
SICA-HF: Studies Investigating Co morbidities Aggravating Heart Failure UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7 Chronic heart failure (CHF) is a massive clinical, social and economic problem. Diabetes and obesity increase the risk of developing CHF. Ca...
Financiado
BIOELECTRICSURFACE: Electrically modified biomaterials surface UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7 According to the World Health Organisation (WHO), cardiovascular diseases cause half the deaths in the EU. It is also the main cause of year...
Financiado
INTREALL: International study for treatment of childhood relapsed ALL 2010 with standard therapy systematic i... UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7 Though survival of children with acute lymphoblastic leukaemia (ALL) has improved, relapse remains a leading cause of mortality in childhood...
Financiado
BIOSTAT-CHF: A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7 Heart failure is common in Europe and its prevalence is increasing as our population ages. Despite major improvements in care since the earl...
Financiado
EPICSTENT: Antibody functionalised cardiovascular stents for improved biocompatibility and reduced restenosis UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU participó en un FP7 An industry-academia collaboration is proposed wherein two industry and three academic partners will establish a lasting, inter-national par...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.